Condition: Alzheimer Disease · Sponsor: Eli Lilly and Company
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Irvine Clinical Research | Irvine, California, United States | Not Yet Recruiting |
| Flinders Medical Centre | Adelaide, Australia | Not Yet Recruiting |
| University of the Sunshine Coast Clinical Trial Centre | Birtinya, Australia | Not Yet Recruiting |
| Austin Health - Heidelberg Repatriation Hospital | Ivanhoe, Australia | Recruiting |
| Southern Neurology | Kogarah, Australia | Recruiting |
| Macquarie University Hospital | Macquarie University, Australia | Recruiting |
| The Alfred | Melbourne, Australia | Recruiting |
| New Zealand Brain Research Institute | Christchurch, New Zealand | Not Yet Recruiting |
| Lilly Centre for Clinical Pharmacology | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07598370